Effectiveness and Safety of Concurrent Use of First-Line Antiretroviral and Antituberculous Drugs in Rwanda
Table 2
Frequency of types of regimen prescribed and their clinical outcomes.
Drug regimens
CD4 changes: (within row %)
Patient outcomes: (within row %)
Total
Gained
Lost
Improved
Unimproved
Died
(between row %)
(%)
(%)
(%)
(%)
(%)
Single-HIV infected ()
60
55
5
47
8
5
3TC+TDF+NVP
25 (41.7)
22 (88.0)
3 (12.0)
20 (80.0)
5 (20.0)
0
3TC+TDF+EFV
32 (53.3)
30 (93.8)
2 (6.3)
24 (75.0)
3 (9.4)
5 (15.6)
3TC+d4T+EFV
3 (5.0)
3 (100)
0
3 (100.0)
0
0
TB/HIV coinfected ()
60
4
56
23
25
12
3TC+TDF+NVP+RHZE
12 (20.0)
0
12 (100)
4 (33.3)
6 (50.0)
2 (16.7)
3TC+TDF+EFV+RHZE
36 (60.0)
4 (11.1)
32 (88.9)
15 (41.7)
11 (30.5)
10 (27.8)
3TC+d4T+EFV+RHZE
2 (3.3)
0
2 (100)
2 (100)
0
0
3TC+ABC+NVP+RHZE
4 (6.7)
0
4 (100)
2 (50.0)
2 (50.0)
0
3TC+AZT+EFV+RHZE
6 (10.0)
0
6 (100)
0
6 (100)
0
Total between row percentage is calculated by dividing the frequency by 60 patients in each group. Within row percentage is calculated by dividing the frequency by the total frequency of each regimen alone.
